Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Generalized anxiety disorder (GAD) is a significant and common mental illness with a lifetime prevalence of 3.7%. Regardless of the complexity of treatment decisions for GAD, few studies have conducted systematic comparisons of the efficacies of varying interventions. Thus, this study performed a valid network meta-analysis (NMA) of randomized controlled trials (RCTs) to synthesize direct and indirect evidence for alternative interventions for GAD. We searched four major bibliographic databases, the Cochrane Central Register of Controlled Trials, Embase, PsycINFO, and PubMed, for published RCTs of adult patients with a diagnosis of GAD and allowed for all comorbidities. A total of 91 articles (14,812 participants) were identified in the final NMA. The results showed that all pharmacological treatments except for serotonin modulators and second-generation antipsychotics had greater effects than placebo: norepinephrine-dopamine reuptake inhibitors (standardized mean difference (SMD) -1.84, 95% credible interval -3.05 to -0.62), noradrenergic and specific serotonergic antidepressants (-0.91, -1.62 to -0.20), melatonergic receptor agonists (-0.68, -1.15 to -0.21), selective serotonin reuptake inhibitors (SSRIs; -0.67, -0.90 to -0.43), azapirones (-0.58, -1.00 to -0.17), anticonvulsants (-0.56, -0.85 to -0.28), serotonin-norepinephrine reuptake inhibitors (SNRIs; -0.54, -0.79 to -0.30), and benzodiazepines (BZDs; -0.40, -0.65 to -0.15). Most psychological and self-help interventions exerted greater effects than the waitlist group. However, no psychological interventions had greater effects compared with the psychological placebo. Overall, most pharmacological interventions had larger effect sizes than psychological interventions, and most psychological interventions showed larger effect sizes than self-help interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Ranking treatments in frequentist network meta-analysis works without resampling methods
Rücker, G., & Schwarzer, G. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0060-8 · Cited by 1,732
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
The Descriptive Epidemiology of Commonly Occurring Mental Disorders in the United States
Kessler, R. C., & Wang, P. S. (2008) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.29.020907.090847 · Cited by 888
Borkovec, T. D., & Costello, E. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.4.611 · Cited by 756
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680 · cited 1×
“Outcome measured using validated instruments including Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959), Generalized Anxiety Disorder 7 (GAD-7) (Spitzer et al., 2006), Penn State Worry Questionnaire (PSWQ) (Meyer et al., 1990).”
MethodBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Cuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M., & Huibers, M. J. H. (2016) · World Psychiatry · doi:10.1002/wps.20346 · Cited by 572 · cited 1×
“…Brown et al., 2015; Butler et al., 1991; Bystritsky et al., 2008; Casacchia et al., 1990; Chen, 2006; Christensen et al., 2014; Conrad et al., 2008; Dahlin et al., 2016; Davidson et al., 2004; Davidson et al., 1999; Dimitriou et al., 1992; Dugas et al., 2003; Dugas et al., 2010; Durgam et al.,…”
BackgroundRoemer, L., Orsillo, S. M., & Salters-Pedneault, K. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0012720 · Cited by 554
Psychological treatment of generalized anxiety disorder: A meta-analysis
Cuijpers, P., Sijbrandij, M., Koole, S., Huibers, M., Berking, M., & Andersson, G. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.01.002 · Cited by 527
Furukawa, T. A., Noma, H., Caldwell, D. M., Honyashiki, M., Shinohara, K., Imai, H., Chen, P., Hunot, V., & Churchill, R. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12275 · Cited by 521
Hoge, E. A., Bui, E., Marques, L., Metcalf, C. A., Morris, L. K., Robinaugh, D. J., Worthington, J. J., Pollack, M. H., & Simon, N. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08083 · Cited by 511 · cited 1×
“Despite structural similarity to imipramine, opipramol does not act as a TCA for it does not impede the neuronal uptake of noradrenaline or serotonin (Holoubek and Müller, 2003; Möller et al., 2001).”
BackgroundRuscio, A. M., Hallion, L. S., Lim, C. C. W., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Andrade, L. H., Borges, G., Bromet, E. J., Bunting, B., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0056 · Cited by 492
Ladouceur, R., Dugas, M. J., Freeston, M. H., Léger, E., Gagnon, F., & Thibodeau, N. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.6.957 · Cited by 446
Human and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Skapinakis, P., Caldwell, D. M., Hollingworth, W., Bryden, P., Fineberg, N. A., Salkovskis, P., Welton, N. J., Baxter, H., Kessler, D., Churchill, R., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30069-4 · Cited by 407
Butler, G., Fennell, M., Robson, P., & Gelder, M. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.167 · Cited by 365
Dugas, M. J., Ladouceur, R., Léger, E., Freeston, M. H., Langolis, F., Provencher, M. D., & Boisvert, J.-M. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.821 · Cited by 331
Thase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331
How to read a funnel plot in a meta-analysis
Sedgwick, P., & Marston, L. (2015) · BMJ · doi:10.1136/bmj.h4718 · Cited by 318
Robinson, E., Titov, N., Andrews, G., McIntyre, K., Schwencke, G., & Solley, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010942 · Cited by 277
van der Heiden, C., Muris, P., & van der Molen, H. T. (2012) · Behaviour Research and Therapy · doi:10.1016/j.brat.2011.12.005 · Cited by 265
Stanley, M. A., Wilson, N. L., Novy, D. M., Rhoades, H. M., Wagener, P. D., Greisinger, A. J., Cully, J. A., & Kunik, M. E. (2009) · JAMA · doi:10.1001/jama.2009.458 · Cited by 247
Cognitive-behavioral treatment of late-life generalized anxiety disorder
Stanley, M. A., Beck, J. G., Novy, D. M., Averill, P. M., Swann, A. C., Diefenbach, G. J., & Hopko, D. R. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.2.309 · Cited by 247
Long-term disability in anxiety disorders
Hendriks, S. M., Spijker, J., Licht, C. M. M., Hardeveld, F., de Graaf, R., Batelaan, N. M., Penninx, B. W. J. H., & Beekman, A. T. F. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0946-y · Cited by 234
Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder
Öst, L.-G., & Breitholtz, E. (2000) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(99)00095-9 · Cited by 229
Dugas, M. J., Brillon, P., Savard, P., Turcotte, J., Gaudet, A., Ladouceur, R., Leblanc, R., & Gervais, N. J. (2010) · Behavior Therapy · doi:10.1016/j.beth.2008.12.004 · Cited by 216 · cited 1×
“…et al., 2008; Dahlin et al., 2016; Davidson et al., 2004; Davidson et al., 1999; Dimitriou et al., 1992; Dugas et al., 2003; Dugas et al., 2010; Durgam et al., 2016; Durham et al., 1994; Feltner et al., 2003; Gao et al., 2017; Gommoll et al., 2015a; Gommoll et al., 2015b; Hartford et al.,…”
Leichsenring, F., Salzer, S., Jaeger, U., Kächele, H., Kreische, R., Leweke, F., Rüger, U., Winkelbach, C., & Leibing, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030441 · Cited by 207
Wells, A., Welford, M., King, P., Papageorgiou, C., Wisely, J., & Mendel, E. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2009.11.013 · Cited by 195
Stanley, M. A., Beck, J. G., & Glassco, J. D. (1996) · Behavior Therapy · doi:10.1016/s0005-7894(96)80044-x · Cited by 184
Wetherell, J. L., Liu, L., Patterson, T. L., Afari, N., Ayers, C. R., Thorp, S. R., Stoddard, J. A., Ruberg, J., Kraft, A., Sorrell, J. T., et al. (2011) · Behavior Therapy · doi:10.1016/j.beth.2010.07.002 · Cited by 175
Humanistic and economic burden of generalized anxiety disorder in North America and Europe
Revicki, D. A., Travers, K., Wyrwich, K. W., Svedsäter, H., Locklear, J., Mattera, M. S., Sheehan, D. V., & Montgomery, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.11.014 · Cited by 172
Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Rüther, E. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601110273 · Cited by 166
Hayes-Skelton, S. A., Roemer, L., & Orsillo, S. M. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0032871 · Cited by 153
Titov, N., Andrews, G., Robinson, E., Schwencke, G., Johnston, L., Solley, K., & Choi, I. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903179269 · Cited by 147
Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder
Hoyer, J., Beesdo, K., Gloster, A. T., Runge, J., Höfler, M., & Becker, E. S. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000201936 · Cited by 147
Paxling, B., Almlöv, J., Dahlin, M., Carlbring, P., Breitholtz, E., Eriksson, T., & Andersson, G. (2011) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2011.576699 · Cited by 147 · cited 1×
“…2008; Montgomery et al., 2006; Nicolini et al., 2009; Nimatoudis et al., 2004; Niu et al., 2004; Ost and Breitholtz, 2000; Paxling et al., 2011; Peng et al., 2006; Pohl et al., 2005; Ramchandran et al., 1990; Richards et al., 2016; Rickels et al., 2005; Rickels et al., 2003; Robinson et al.,…”
BackgroundEfficacy of Cognitive Behaviour Therapy in Generalized Anxiety Disorders
Linden, M., Zubraegel, D., Baer, T., Franke, U., & Schlattmann, P. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082025 · Cited by 142
Generalized anxiety disorder in urban China: Prevalence, awareness, and disease burden
Yu, W., Singh, S. S., Calhoun, S., Zhang, H., Zhao, X., & Yang, F. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.012 · Cited by 119
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Zinbarg, R. E., Eun Lee, J., & Lira Yoon, K. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2006.06.005 · Cited by 95
Dahlin, M., Andersson, G., Magnusson, K., Johansson, T., Sjögren, J., Håkansson, A., Pettersson, M., Kadowaki, Å., Cuijpers, P., & Carlbring, P. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2015.12.007 · Cited by 86 · cited 1×
“…et al., 2008; Casacchia et al., 1990; Chen, 2006; Christensen et al., 2014; Conrad et al., 2008; Dahlin et al., 2016; Davidson et al., 2004; Davidson et al., 1999; Dimitriou et al., 1992; Dugas et al., 2003; Dugas et al., 2010; Durgam et al., 2016; Durham et al., 1994; Feltner et al.,…”
Chartrand, H., Sareen, J., Toews, M., & Bolton, J. M. (2012) · Depression and Anxiety · doi:10.1002/da.20882 · Cited by 86 · cited 1×
“Finally, GAD has also been demonstrated to be a strong risk factor for suicide, because the suicide rate is higher in patients with GAD compared with those without anxiety (Chartrand et al., 2012; Kanwar et al., 2013).”
BackgroundAvdagic, E., Morrissey, S. A., & Boschen, M. J. (2014) · Behaviour Change · doi:10.1017/bec.2014.5 · Cited by 74
Agomelatine in Generalized Anxiety Disorder: An Active Comparator and Placebo-Controlled Study
Stein, D. J., Ahokas, A., Márquez, M. S., Höschl, C., Oh, K. S., Jarema, M., Avedisova, A. S., Albarran, C., & Olivier, V. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08433 · Cited by 67
Agomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Research works printed but not linked: 93
- Alaka, 2014, Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial, Int. J. Geriatr. Psychiatry, 29, 978, 10.1002/gps.4088 · DOI · Paper page
- Aliyev, 2008, Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study, Eur. Psychiatry, 23, 109, 10.1016/j.eurpsy.2007.08.001 · DOI · Paper page
- Allgulander, 2004, Efficacy of sertraline in a 12-week trial for generalized anxiety disorder, Am. J. Psychiatry, 1642, 10.1176/appi.ajp.161.9.1642 · DOI · Paper page
- Andersson, 2012, Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial, Psychother. Psychosom., 81, 344, 10.1159/000339371 · DOI · Paper page
- Antunes, 2018, Disability and common mental disorders: results from the world mental health survey initiative Portugal, Eur. Psychiatry : J. Assoc. Eur. Psychiatrists, 49, 56, 10.1016/j.eurpsy.2017.12.004 · DOI · Paper page
- Baldwin, 2011, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ, 342, d1199, 10.1136/bmj.d1199 · DOI · Paper page
- Bidzan, 2012, Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial, Eur. Neuropsychopharmacol., 22, 847, 10.1016/j.euroneuro.2012.07.012 · DOI
- Black, 2006, Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders, CNS Spectr., 11, 29, 10.1017/S1092852900025827 · DOI · Paper page
- Brawman-Mintzer, 2006, Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychiatry, 874, 10.4088/JCP.v67n0603 · DOI · Paper page
- Brenes, 2015, Telephone-delivered cognitive behavioral therapy and telephone-delivered nondirective supportive therapy for rural older adults with generalized anxiety disorder: a randomized clinical trial, JAMA Psychiatry, 72, 1012, 10.1001/jamapsychiatry.2015.1154 · DOI · Paper page
- Brown, 2015, Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder, Psychiatry Res., 394, 10.1016/j.pscychresns.2015.06.016 · DOI
- Bystritsky, 2008, A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder, Psychopharmacol. Bull., 46
- Chen, 2006, A comparative study of paroxetine and alprazolam in the treatment of patients with generalized anxiety disorder, J. heze Med. Coll., 18
- Christensen, 2014, The effectiveness of an online e-health application compared to attention placebo or Sertraline in the treatment of Generalised Anxiety Disorder, Internet Interv., 1, 169, 10.1016/j.invent.2014.08.002 · DOI · Paper page
- Conrad, 2008, The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxation, Psychophysiology, 377, 10.1111/j.1469-8986.2007.00644.x · DOI
- Correll, 2011, Antipsychotic drugs and obesity, Trends Mol. Med., 17, 97, 10.1016/j.molmed.2010.10.010 · DOI · Paper page
- Crits-Christoph, 2011, Combined medication and cognitive therapy for generalized anxiety disorder, J. Anxiety Disord., 25, 1087, 10.1016/j.janxdis.2011.07.007 · DOI · Paper page
- Davidson, 1999, Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder, J. Clin. Psychiatry, 528, 10.4088/JCP.v60n0805 · DOI · Paper page
- Davidson, 2004, Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study, Depress. Anxiety, 234, 10.1002/da.10146 · DOI · Paper page
- Diefenbach, 2016, Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial, Br. J. Psychiatry, 209, 222, 10.1192/bjp.bp.115.168203 · DOI · Paper page
- Dilkov, 2017, Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: a randomized, double-blind sham controlled clinical trial, Prog. Neuro Psychopharmacol. Biol. Psychiatry, 78, 61, 10.1016/j.pnpbp.2017.05.018 · DOI
- Dimitriou, 1992, Buspirone vs alprazolam: a double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms, Drug Invest., 316, 10.1007/BF03259411 · DOI
- Durgam, 2016, Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial, J. Clin. Psychiatry, 77, 1687, 10.4088/JCP.15m09885 · DOI · Paper page
- Durham, 1994, Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder, Br. J. Psychiatry, 315, 10.1192/bjp.165.3.315 · DOI · Paper page
- Feighner, 1995, Cardiovascular safety in depressed patients: focus on venlafaxine, J. Clin. Psychiatry, 56, 574
- Feltner, 2003, A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 240, 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
- Freiesleben, 2015, A systematic review of agomelatine-induced liver injury, J. Mol. Psychiatry, 3, 4, 10.1186/s40303-015-0011-7 · DOI · Paper page
- Fulton, 1997, Buspirone: an updated review of its clinical pharmacology and therapeutic applications, CNS Drugs, 7, 68, 10.2165/00023210-199707010-00007 · DOI
- Gao, 2017, A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use, Psychopharmacology, 234, 2233, 10.1007/s00213-017-4642-5 · DOI
- Gommoll, 2015, A double-blind, randomized, placebo-controlled, fixed-dose phase iii study of vilazodone in patients with generalized anxiety disorder, Depress. Anxiety, 32, 451, 10.1002/da.22365 · DOI · Paper page
- Gommoll, 2015, Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study, Int. Clin. Psychopharmacol., 30, 297, 10.1097/YIC.0000000000000096 · DOI · Paper page
- Hamer, 2011, Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey, Eur. Heart J., 32, 437, 10.1093/eurheartj/ehq438 · DOI · Paper page
- Hamilton, 1959, The assessment of anxiety states by rating, Br. J. Med. Psychol., 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/YIC.0b013e32807fb1b2 · DOI · Paper page
- Holoubek, 2003, Specific modulation of sigma binding sites by the anxiolytic drug opipramol, J. Neural Transm., 110, 1169, 10.1007/s00702-003-0019-5 · DOI
- Huang, 2006, A comparison study of sertraline, venlafaxine and alprazolam in treatment of generalized anxiety disorder, Chin. J. Behav. Med. Sci., 376, 332
- Ji, 2004, Randomized, double blind controlled trial of trazodone versus alprazolam in the treatment of generalized anxiety disorder, Chin. J. Evidence-Based Med., 528
- Jiang, 2010, Randomized controlled trial of mono-therapy quetiapine versus mono-therapy paroxetine in the treatment of generalized anxiety disorder, Shanghai Arch. Psychiatry, 22, 295
- Kanwar, 2013, The association between anxiety disorders and suicidal behaviors: a systematic review and meta-analysis, Depress. Anxiety, 30, 917
- Kasper, 2009, Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial, Int. Clin. Psychopharmacol., 24, 87, 10.1097/YIC.0b013e32831d7980 · DOI · Paper page
- Kasper, 2014, Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder, Int. J. Neuropsychopharmacol., 17, 685, 10.1017/S1461145713001557 · DOI
- Keefe, 2014, A meta-analytic review of psychodynamic therapies for anxiety disorders, Clin. Psychol. Rev., 34, 309, 10.1016/j.cpr.2014.03.004 · DOI
- Laporte, 2017, Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies, Pharmacol. Res., 118, 19, 10.1016/j.phrs.2016.08.017 · DOI · Paper page
- Lenze, 2009, Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial, JAMA, J. Am. Med. Assoc., 301, 295, 10.1001/jama.2008.977 · DOI · Paper page
- Li, 2004, A comparison study of citalopram versus alprazolam in the treatment of generalized anxiety disorder, Shandong Arch. Psychiatr., 87
- Li, 2004, Tandospirone for treatment of generalized anxiety: a randomized, double blind and controlled study on the curative effect and reliability, Chin. J. Clin. Rehabil., 4176
- Li, 2005, A comparison study of sertraline versus alprazolam in the treatment of generalized anxiety disorder, Shandong Arch. Psychiatr., 145
- Li, 2005, A comparative study of paroxetine and clonazepam in the treatment of patients with generalized anxiety disorder, Shandong Arch. Psychiatr., 252
- Li, 2016, A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder, Psychopharmacol. Bull., 46, 8
- Lieb, 2005, The epidemiology of generalized anxiety disorder in Europe, Eur. Neuropsychopharmacol. : J. Eur. Coll. Neuropsychopharmacol., 15, 445, 10.1016/j.euroneuro.2005.04.010 · DOI · Paper page
- Liu, 2005, A comparative study between mirtazapine and buspirone in the treatment of generalized anxiety disorder, Med. J. Chin. Health People, 495
- Mahableshwarkar, 2014, A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder, Int. J. Clin. Pract., 68, 49, 10.1111/ijcp.12328 · DOI · Paper page
- Mahableshwarkar, 2014, A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder, Hum. Psychopharmacol., 29, 64, 10.1002/hup.2371 · DOI · Paper page
- Meyer, 1990, Development and validation of the Penn state worry Questionnaire, Behav. Res. Ther., 28, 487, 10.1016/0005-7967(90)90135-6 · DOI · Paper page
- Mokhber, 2010, Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder, Psychiatry Clin. Neurosci., 64, 128, 10.1111/j.1440-1819.2009.02055.x · DOI · Paper page
- Möller, 2001, Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group, J. Clin. Psychopharmacol., 21, 59, 10.1097/00004714-200102000-00011 · DOI · Paper page
- Montgomery, 2006, Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine, J. Clin. Psychiatry, 771, 10.4088/JCP.v67n0511 · DOI · Paper page
- Montgomery, 2008, Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder, Br. J. Psychiatry, 193, 389, 10.1192/bjp.bp.107.037788 · DOI · Paper page
- Nicolini, 2009, Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial, Psychol. Med., 267, 10.1017/S0033291708003401 · DOI · Paper page
- Nimatoudis, 2004, Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study, Int. Clin. Psychopharmacol., 331, 10.1097/00004850-200411000-00003 · DOI · Paper page
- Niu, 2004, Comparison of efficacy of mirtazapine and fluoxetine in treatment of depression with generalized anxiety disorder, Chin. J. N. Drugs Clin. Remedies, 853
- Pae, 2015, Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis, J. Psychiatr. Res., 64, 88, 10.1016/j.jpsychires.2015.02.017 · DOI
- Peng, 2006, A controlled study of paroxetine and flunipam in the treatment of generalized anxiety disorder, J. Clin. Psychosom. Dis., 169
- Pohl, 2005, Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing, J. Clin. Psychopharmacol., 151, 10.1097/01.jcp.0000155820.74832.b0 · DOI · Paper page
- Ramchandran, 1990, Comparative clinical evaluation of buspirone and diazepam in generalized anxiety disorders, Curr. Ther. Res. Clin. Exp., 502
- Reinhold, 2015, Pharmacological treatment for generalized anxiety disorder in adults: an update, Expert Opin. Pharmacother., 16, 1669, 10.1517/14656566.2015.1059424 · DOI · Paper page
- Richards, 2016, Effectiveness of an internet-delivered intervention for generalized anxiety disorder in routine care: a randomised controlled trial in a student population, Internet Interv., 6, 80, 10.1016/j.invent.2016.10.003 · DOI · Paper page
- Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam, Arch. Gen. Psychiatr., 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
- Rickels, 2003, Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study, Am. J. Psychiatry, 749, 10.1176/appi.ajp.160.4.749 · DOI · Paper page
- Rickels, 2005, Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam, Arch. Gen. Psychiatr., 1022, 10.1001/archpsyc.62.9.1022 · DOI · Paper page
- Rocca, 1997, Paroxetine efficacy in the treatment of generalized anxiety disorder, Acta Psychiatr. Scand., 95, 444, 10.1111/j.1600-0447.1997.tb09660.x · DOI · Paper page
- Roose, 2016, Selective serotonin reuptake inhibitors and operative bleeding risk: a review of the literature, J. Clin. Psychopharmacol., 36, 704, 10.1097/JCP.0000000000000575 · DOI
- Rosenthal, 2003, Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control, J. Clin. Psychiatry, 1245, 10.4088/JCP.v64n1016 · DOI · Paper page
- Ross, 1987, A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder, Can. J. Psychiatr. Rev. Canad. Psychiatr., 351, 10.1177/070674378703200505 · DOI · Paper page
- Rothschild, 2012, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur. Neuropsychopharmacol., 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
- Shen, 1999, Clinical study on buspirone hydrochloride treated for generalized anxiety disorder, J. Chin. Civil Adm. Med., 70
- Shi, 2004, Venlafaxine compared to alprazolam in the treatment of generalized anxiety disorder, Shanghai Arch. Psychiatr., 215
- Spitzer, 2006, A brief measure for assessing generalized anxiety disorder: the GAD-7, Arch. Intern. Med., 166, 1092, 10.1001/archinte.166.10.1092 · DOI · Paper page
- Stanley, 2003, Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings, Am. J. Geriatr. Psychiatry, 92
- Stein, 2015, CLINICAL PRACTICE. Generalized anxiety disorder, N. Engl. J. Med., 373, 2059, 10.1056/NEJMcp1502514 · DOI · Paper page
- Stein, 2008, Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 28, 561, 10.1097/JCP.0b013e318184ff5b · DOI · Paper page
- Stein, 2017, Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study, Eur. Neuropsychopharmacol., 27, 526, 10.1016/j.euroneuro.2017.02.007 · DOI · Paper page
- Taylor, 2008, Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety, Acta Psychiatr. Scand., 118, 434, 10.1111/j.1600-0447.2008.01260.x · DOI · Paper page
- Wang, 2003, A comparative study between venlafaxine and alprazolam in the treatment of generalized anxiety disorder, J. Clin. Psychol. Med., 155
- Wang, 2004, A clinical control study of paroxetine and clonazepam in the treatment of generalized anxiety disorder, Chin. J. Psychol. Health, 359, 365
- Weizhen, 2004, A comparative study of paroxetine and lorazepam in the treatment of generalized anxiety disorder, Chin. Ment. Health J., 18, 740
- Wetherell, 2003, Treatment of generalized anxiety disorder in older adults, J. Consult. Clin. Psychol., 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
- Wu, 2011, Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China, Chin. Med. J., 124, 3260
- Yin, 2005, The clinical comparison of citalopram with estazolam in the efficacy for generalized anxiety disorder, J. Jinggangshan Univ., 105
- Zareifopoulos, 2017, Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis, Asian J. Psychiatr, 26, 115, 10.1016/j.ajp.2017.01.016 · DOI
- Zargar, 2012, Effect of acceptance-based behavior therapy on severity of symptoms, worry and quality of life in women with generalized anxiety disorder, Iran. J. Psychiatry Behav. Sci., 6, 23
- Zeng, 2003, Paroxetine versus alprazolam in treatment of generalized anxiety disorder, Sichuan Ment. Health, 135
- Zullino, 2015, Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes, Psychiatr. Q., 86, 69, 10.1007/s11126-014-9334-2 · DOI
Cited by
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Eilert, N., Enrique, A., Wogan, R., Mooney, O., Timulak, L., & Richards, D. (2021) · Depression and Anxiety · doi:10.1002/da.23115 · Cited by 60
“…are several recent meta‐analyses of psychological treatments of GAD, some of which included Internet‐delivered interventions (e.g., Carl et al., 2020; Chen et al., 2019; Hall et al., 2016), none specifically set out to evaluate all available evidence for Internet‐delivered interventions (e.g.,…”
Background
Metadata
- Authors
- Chen, T.-R., Huang, H.-C., Hsu, J.-H., Ouyang, W.-C., & Lin, K.-C.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 118
- Pages
- 73-83
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2971709403
- Cited by
- 54
- References
- 47
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.